Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2021

View Archived Issues

Health Canada approves clinical trials of AT-1501 in kidney transplantation

Interim update on first-in-human study of SB-11285 in solid tumors

PolarityTE submits IND for SkinTE in chronic cutaneous ulcers

Yeast study reveals potential cancer therapy approach

Japan Tobacco divulges new NLRP3 inflammasome inhibitors

Beijing Scitech-Mq Pharmaceuticals identifies new FGFR4 inhibitors

New DGAT-2 inhibitors discovered at LG Chem

Ophirex initiates phase II study of varespladib in severe COVID-19

Jiangsu Simcere Pharmaceutical R&D describes TGF-beta receptor type-1 inhibitors

Cerecor reports initial phase Ib data on CERC-002 in moderate to severe Crohn's disease

Leo Pharma begins phase IIa study of LEO-138559 for moderate to severe atopic dermatitis

XWPharma starts first-in-human study of XW-10508

Inozyme opens enrollment in phase I/II study of INZ-701 for ENPP1 deficiency

Responses seen with personalized neoantigen peptide vaccine in NSCLC patients with EGFR mutations

Enrollment opens in phase I study of BI-1569912 for major depressive disorder

Inhalable human ACE2-containing nanocatchers may protect host cells from SARS-CoV-2 infection

First-in-human safety and PK data reported for pirepemat

Xenon Pharmaceuticals targets Nav1.5 with aryl sulfonamide inhibitors

Grunenthal begins phase I trial of glucocorticoid receptor modulator

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...